Evaluation of ABT-751 against childhood cancer models in vivo

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 285-295

  Morton, Christopher L ^a   Favours, Edward G ^a   Mercer, Kimberly S ^a   Boltz, Claire R ^a   Crumpton, Jeri Carol ^a   Tucker, Chandra ^a   Billups, Catherine A ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ABT 751; Pediatric preclinical testing; Xenogarft

Indexed keywords

N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG EFFICACY; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MEDULLOBLASTOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR MODEL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIMITOTIC AGENTS; CELL LINE, TUMOR; CHILD; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PEDIATRICS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250618323     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9042-y     Document Type: Article

References (22)

1. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N (1998) Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 89(9):954-962
2. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57(15):3208-3213
3. Gwaltney SL, 2nd, Imade HM, Li Q, Gehrke L, Credo RB, Warner RB, Lee JY, Kovar P, Frost D, Ng SC, Sham HL (2001) Novel sulfonate derivatives: potent antimitotic agents. Bioorg Med Chem Lett 11(13):1671-1673
4. Funahashi Y, Koyanagi N, Kitoh K (2001) Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother Pharmacol 47(2):179-184
5. Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54(7):1702-1706
6. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27(4):482-487
7. Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer (Suppl) 27:S86-S88
8. Hill SA, Sampson LE, Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63(1):119-123
9. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1994) The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol 345:417-422
10. Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA (2004) Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54(3):273-281
11. Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D (2006) Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol, in press. DOI 10.1007/s00280-006-0326- 2
12. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ (2005) Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-6624
13. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12(9):2834-2840
14. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM (2006) A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12(16):4882-4887
15. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA (2006) The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer, in press. DOI 10.1002/pbc.21078
16. Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40(6):837-844
17. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA (2002) Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8(12):3646-3657
18. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17(6):1815-1824
19. Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, Stewart CF (2005) Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23(18):4039-4047
20. Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB (1996) Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 14(1):37-47
21. Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8(4):313-322
22. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ (2006) SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer, in press. DOI 10.1002/pbc.21099